Radioiodinated Persistent Luminescence Nanoplatform for Radiation-Induced Photodynamic Therapy and Radiotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32691987.
- Also identified by DOI 10.1002/adhm.202000802.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radionuclide with Cerenkov radiation (CR) can serve as an internal excitation source to activate photosensitizers for photodynamic therapy (PDT) in deep tumor. However, the low efficiency of CR limits its therapeutic efficacy. A <sup>131</sup> I labeled zinc tetra(4-carboxyphenoxy) phthalocyaninate (ZnPcC4) conjugated Cr<sup>3+</sup> -doped zinc gallate (ZnGa<sub>2</sub> O<sub>4</sub> :Cr<sup>3+</sup> , ZGCs) nanoplatform (<sup>131</sup> I-ZGCs-ZnPcC4) is developed for radiotherapy (RT) and radiation-induced PDT. <sup>131</sup> I can not only activate ZGCs for long-lasting luminescence via both Cerenkov luminescence (CL) and ionizing radiation, which further continuously activate photosensitizer ZnPcC4 for PDT, but also can directly kill cancerous cells. This <sup>131</sup> I-ZGCs-ZnPcC4 exhibits excellent tumor inhibition both in vitro and in vivo. Combining self-activated PDT and RT, it is believed that the <sup>131</sup> I-ZGCs-ZnPcC4 can greatly benefit the deep tumor therapy.
Medical subject headings
- Nanoparticles
- Neoplasms
- Photochemotherapy